Welcome to our dedicated page for ZIOP news (Ticker: ZIOP), a resource for investors and traders seeking the latest updates and insights on ZIOP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZIOP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZIOP's position in the market.
Ziopharm Oncology, Inc. (Nasdaq: ZIOP) has sent a letter urging shareholders to support its long-term prospects amidst a consent solicitation initiated by WaterMill Asset Management. The Board has accepted the resignation of Director Elan Ezickson and expressed concerns over WaterMill nominee Holger Weis's professional history. Ziopharm emphasizes its commitment to resolving the situation amicably and has engaged with shareholders to enhance governance. The company believes its Board, recently refreshed with qualified directors, is equipped to guide its growth in cancer treatment.
WaterMill Asset Management, holding about 3.3% of Ziopharm Oncology (ZIOP), has responded to an alleged smear campaign by the current Board against Holger Weis. The firm emphasizes the necessity for board changes, as supported by ISS, which recommends voting for WaterMill's nominees and removing two incumbents. Prominent figures from the biotech sector endorse Weis, praising his integrity and leadership. WaterMill contends that the Board's claims against Weis are misleading and unsubstantiated, arguing for shareholder support for their proposals before the December 11 deadline.
Ziopharm Oncology (Nasdaq: ZIOP) responds to an Institutional Shareholder Services (ISS) report regarding a consent solicitation initiated by WaterMill Asset Management. The ISS recommends that shareholders reject WaterMill's proposal to remove half of the board, citing Ziopharm's recent outperformance relative to peers under Chairman Scott Tarriff. However, the company disputes several inaccuracies in the ISS report, particularly concerning board attendance and management transitions. Ziopharm urges shareholders to use the GREEN Consent Revocation Card to maintain the current board's leadership.
WaterMill Asset Management, owning approximately 3.3% of Ziopharm Oncology (ZIOP), has released a rebuttal against the incumbent Board's claims about its partnership with Intrexon, now Precigen. WaterMill aims to replace four directors with independent nominees, arguing that the current Board has misled shareholders and failed to deliver meaningful clinical progress, resulting in a 76% decline in equity value over five years. They emphasize the need for urgent change to restore shareholder trust and accountability.
Ziopharm Oncology (Nasdaq: ZIOP) has filed an investor presentation with the SEC, showcasing its oncology development progress and governance enhancements aimed at boosting shareholder value. The presentation highlights significant advances in non-viral and cytokine-driven therapies since separating from Precigen in 2018, with upcoming milestones expected to enhance shareholder value. Recent board changes include new director appointments and addressing shareholder feedback. Analysts affirm ZIOP's potential in personalized cancer therapy and clinical trial readiness.
WaterMill Asset Management Corp., owning approximately 3.3% of Ziopharm Oncology (NASDAQ: ZIOP), has released a 55-page presentation advocating for significant board changes. WaterMill aims to remove four current directors and elect three independent candidates to enhance governance and financial standing. The presentation outlines concerns about the incumbent board, highlighting a troubling cash position and rising expenses. It emphasizes the need for improved governance practices and a disciplined capital allocation strategy to avert potential financial disaster and deliver shareholder value.
Ziopharm Oncology announced positive interim data from three ongoing clinical trials of Controlled IL-12 for treating recurrent glioblastoma (rGBM) and diffuse intrinsic pontine glioma (DIPG). The Phase 2 study with cemiplimab shows promising safety and a confirmed partial response. In a Phase 1 study combining Controlled IL-12 with nivolumab, the median overall survival (mOS) reached 16.9 months. Early results from a Phase 1/2 study on Controlled IL-12 monotherapy in DIPG indicate safety and immune system activation. Further data is anticipated in 2021.
Ziopharm Oncology has appointed Raffaele Baffa, M.D., Ph.D., as its new Chief Medical Officer. Dr. Baffa brings over 20 years of experience in clinical research, previously serving as Chief Medical Officer for Servier Pharmaceuticals and holding senior roles at Pfizer and Sanofi. His expertise includes engineered T cells and regulatory filings, having led multiple IND submissions and regulatory approvals in oncology. This leadership change is anticipated to enhance Ziopharm's capabilities in advancing its cancer therapies, leveraging Dr. Baffa's profound knowledge and extensive background in the field.
Ziopharm Oncology (Nasdaq: ZIOP) has appointed Mary Thistle as an Independent Director on its Board. Thistle, with over 25 years in biotechnology, previously held key roles at the Bill & Melinda Gates Medical Research Institute and Dimension Therapeutics. Her expertise in business development is expected to enhance the company’s strategy. Scott Braunstein has stepped down from the Board. This transition reflects the Board's commitment to rejuvenation and diversity, aiming to drive clinical and commercial success in Ziopharm's innovative cancer treatment pipeline.
BOSTON, Nov. 13, 2020 – Ziopharm Oncology (Nasdaq: ZIOP) announced that Laurence Cooper, M.D., Ph.D., CEO, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 1:45 pm ET. Investors can access the live webcast and archived recording on the company’s website.
Ziopharm is focused on developing non-viral and cytokine-driven cell therapies to treat solid tumors, utilizing the Sleeping Beauty gene transfer platform for scalable therapies, with partnerships in clinical research.
